Vera Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
VERA$30.03-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(28,383) | $(30,069) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation, amortization and accretion | (1,469) | (506) |
| Reduction in the carrying amount of operating lease right-of-use assets | 517 | 579 |
| Stock-based compensation | 4,124 | 2,667 |
| Changes in operating assets and liabilities: | ||
| Prepaid expense and other current assets | (392) | 3,749 |
| Other assets | 9 | (4) |
| Accounts payable | (5,909) | (6,665) |
| Accrued and other current liabilities | (1,690) | 4,637 |
| Operating lease liabilities | (637) | (680) |
| Net cash used in operating activities | (33,830) | (26,292) |
| Cash flows from investing activities | ||
| Purchase of marketable securities | (254,967) | (34,209) |
| Proceeds from maturities of marketable securities | 31,681 | 36,900 |
| Proceeds from sale of marketable securities | 4,000 | 9,543 |
| Net cash (used in) provided by investing activities | (219,286) | 12,234 |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 6,911 | 240 |
| Proceeds from short swing settlement | 37 | — |
| Proceeds from issuance of common stock in follow-on offering | 287,500 | 115,000 |
| Payment of costs and underwriting discounts and commissions related to follow-on offering | (17,908) | (7,256) |
| Net cash provided by financing activities | 276,540 | 107,984 |
| Net increase in cash and cash equivalents and restricted cash | 23,424 | 93,926 |
| Cash, cash equivalents and restricted cash, beginning of period | 45,681 | 43,752 |
| Cash, cash equivalents and restricted cash, end of period | $69,105 | $137,678 |
| Reconciliation of cash and cash equivalents and restricted cash to the balance sheets | ||
| Cash and cash equivalents | $69,105 | $137,385 |
| Restricted cash | — | 293 |
| Total cash and cash equivalents and restricted cash | $69,105 | $137,678 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest expense | $1,520 | $3,253 |
| Cash paid for operating leases | $764 | $746 |
| Receivable on exercise of stock options | $13 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.